GlucoTrack Inc

GCTK | $0.8191 22.25% 18.2% 190K

(0.0% 1d) (145.0% 1m) (17.1% 1y) (0.0% 2d) (15.5% 3d) (82.2% 7d) (-70.31% volume)
Earnings Calendar:
Market Cap: $ 21,916,142
https://www.integrity-app.com
Sec Filling | Patents | 11 employees

(IL) Integrity Applications, Inc. was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.

diabetes diabetic

add to watch list Paper trade email alert is off

Humacyte Inc

HUMA | $3.7 3.06% 2.97% 4.9M

Manufacturing

(0.0% 1d) (2.8% 1m) (11.8% 1y) (3.1% 2d) (18.6% 3d) (28.9% 7d) (-15.47% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 440,609,794
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

Intelligent Bio Solutions Inc

INBS | $2.71 -3.21% -3.32% 58K

Manufacturing

(0.0% 1d) (-25.3% 1m) (-11.3% 1y) (-2.1% 2d) (2.2% 3d) (-16.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 7,707,928
https://gbs.inc
Sec Filling | Patents | 8 employees

(US) GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

diagnostics diabetes diabetic covid

add to watch list Paper trade email alert is off

PharmaCyte Biotech Inc

PMCB | $2.2 0.0% 11K

Manufacturing

(0.0% 1d) (-12.0% 1m) (-28.9% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (20.64% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 18,597,471
https://www.pharmacytebiotech.com
Sec Filling | Patents | 4 employees

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.

diabetic diabetes msa ceiling cancer genetic t-cell

add to watch list Paper trade email alert is off

Aadi Biosciences Inc

AADI | $1.835 1.94% 1.91% 140K

Manufacturing

(0.0% 1d) (-14.4% 1m) (-76.9% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (11.51% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 45,056,966
https://www.aerpio.com
Sec Filling | Patents | 12 employees

(US) Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

monoclonal antibodies antibody treatment diabetic diabetes injection macular

add to watch list Paper trade email alert is off